Bracco Imaging earns its first EcoVadis Platinum Medal: in Global Top 1%

Join us @ RSNA 2025 At RSNA 2025, Bracco Diagnostics Inc. is proud to spotlight its unwavering dedication to two distinct pillars shaping the future of radiology: education and sustainability. 

RSNA 2025 - Cloned

Scientific Information Inquiry Fill in this form to receive information about medical and clinical aspects of a product.

Bracco Shapes the Future of Radiology at RSNA 2025 Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, will showcase a bold vision for radiology at the Radiological Society of North America (RSNA) 2025 Annual Meeting, to be held November 30 – December 4 in Chicago, Illinois.

Bracco Delivers 3 Million VUEWAY® Doses, Meeting Patient Demand for Lower-Dose MRI Contrast Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a global leader in diagnostic imaging, announced today that more than three million doses1 of its magnetic resonance imaging (MRI) agent, VUEWAY® (gadopiclenol) solution for injection, intravenous use, have been administered across 902 customer sites.2

FDA Approves Expanded Indication for Max 3™ Syringeless MR Injector from Bracco FDA Approval of VUEWAY® (gadopiclenol) injection Imaging Bulk Package (IBP) Enhances Options for Efficient, Sustainable MRI Contrast Delivery.

CMS Doubles Payment for Contrast-Enhanced Ultrasound Scans Provided by Business Wire - 25 November 2025

Cell Therapy Target hard to isolate cell populations and subpopulations with our bead free, column free microbubble-based cell selection and activation technology. Our lipid based microbubbles provide a non-magnetic approach to cell selection and activation across cell therapy workflows.

Innovation in Cell Therapy: Bracco Imaging Forms Strategic Partnership with CellBri We’re proud to announce a new partnership between Bracco Imaging Medical Technologies (Shanghai) and Shenzhen Cellbri Bio-Innovation Technology, aimed at transforming CAR-T cell therapy manufacturing — one of the most promising areas in personalized cancer treatment.